Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sensei Biotherapeutics, Inc. filings document a Nasdaq-listed clinical-stage oncology company, its common stock, and its disclosure obligations around pipeline development, operating results, governance, and capital structure. Material-event reports cover financial results, Regulation FD disclosures, board composition and compensation arrangements, and the completed acquisition of Faeth Therapeutics, including acquired-business financial statements and pro forma combined financial information.
Proxy and governance filings describe shareholder voting matters, director and board matters, equity compensation, preferred stock conversion-related disclosures, authorized-share matters, material agreements, and other capital-structure topics. The filing record also reflects clinical and regulatory disclosure categories for PIKTOR and solnerstotug within the company’s oncology development business.
Sensei Biotherapeutics, Inc. filed an initial insider ownership report for Parikh Anand Kiran. The filing identifies him as both a director and the Chief Operating Officer of the company. This Form 3 does not report any specific stock transactions or share amounts.
James Peyer filed a Form 144 reporting a proposed sale of 950 common shares on 02/18/2026. The filing lists the sale as an option granted 06/11/2024 and names Fidelity Brokerage Services LLC as the broker. The excerpt also shows prior sales of 841 common shares on 12/09/2025 for $6,706.72.
Sensei Biotherapeutics is transforming its business by acquiring Faeth Therapeutics and raising about $200 million in a concurrent private placement of Series B non-voting convertible preferred stock. These preferred shares are each convertible into 1,000 common shares if stockholders later approve the needed proposals.
After the merger and financing, former Faeth holders and new investors will own the vast majority of Sensei, while existing stockholders drop to about 4.9% of the fully diluted common stock. The deal makes Faeth’s lead cancer drug PIKTOR Sensei’s main program, with funding aimed at Phase 2 endometrial cancer data and a Phase 1b breast cancer trial by year-end 2026.
Donenberg Phillip B. reported acquisition or exercise transactions in a Form 4 filing for SNSE. The filing lists transactions totaling 1,900 shares. Following the reported transactions, holdings were 1,900 shares.
Sensei Biotherapeutics, Inc. director Phillip B. Donenberg filed an initial Form 3 reporting his beneficial ownership of the company’s securities as of February 13, 2026. The filing states that no securities are beneficially owned and lists no derivative positions or transactions.
Sensei Biotherapeutics, Inc. expanded its board of directors from three to five members and appointed Christopher W. Gerry and Phillip B. Donenberg as new directors, effective immediately. Gerry is the Company’s President, Principal Executive Officer and General Counsel, with prior legal and biotech experience. Donenberg brings extensive financial leadership and public company board experience in gene therapy and therapeutics. Donenberg will receive compensation under Sensei’s standard non-employee director program, and both new directors will enter into the Company’s standard form of indemnification agreement.
Sensei Biotherapeutics security holder plans a small stock sale under Rule 144. The notice covers the proposed sale of 1,169 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 11,485.83.
The shares were acquired through restricted stock vesting from the issuer on several dates between 03/09/2023 and 03/09/2025 as compensation. The person filing represents that they are not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
Sensei Biotherapeutics, Inc. (SNSE) reported the initial shareholdings of its President and Principal Executive Officer as of 11/14/2025. The executive directly beneficially owns 1,574 shares of common stock, primarily in the form of restricted stock units, with 1,444 shares already vested and 130 shares scheduled to vest in two equal installments on February 15, 2026 and February 15, 2027, subject to continued service.
The executive also holds multiple stock options to purchase common stock with different exercise prices and vesting schedules. These options cover separate grants that generally vest monthly over thirty-six months from their respective commencement dates, with one grant vesting 100% on December 1, 2025, all conditioned on continued service with Sensei Biotherapeutics.
Sensei Biotherapeutics (SNSE) reported Q3 results and outlined major changes to its business. The company posted a net loss of $4.569M, improved from $7.253M a year ago, as operating expenses fell to $4.851M. Cash, cash equivalents and marketable securities totaled $25.0M as of September 30, 2025.
Sensei discontinued development of its lead program, solnerstotug, and began a review of strategic alternatives, which could include asset sales, licensing, a merger, or an orderly wind-down. To preserve cash, it plans a workforce reduction of approximately 65%, expecting cash charges of about $1.6M primarily for severance. Management concluded there is substantial doubt about the company’s ability to continue as a going concern.
The company effected a 1‑for‑20 reverse stock split on June 16, 2025. Shares outstanding were 1,261,290 as of November 10, 2025. With R&D at $2.536M and G&A at $2.315M in Q3, Sensei expects lower expenses as operations wind down during the strategic review.
Sensei Biotherapeutics (SNSE) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025. The disclosure appears under Item 2.02, with the company stating the information "shall not be deemed filed" for purposes of Section 18 of the Exchange Act.
The press release is included as Exhibit 99.1. Sensei’s common stock trades on Nasdaq under the symbol SNSE.